Clinical Scorecard: Expanding the Role of Suprachoroidal Injections
At a Glance
| Category | Detail |
|---|---|
| Condition | Uveitic macular edema and other macular disorders |
| Key Mechanisms | Targeted drug delivery via the suprachoroidal space (SCS) minimizes exposure to anterior-segment structures. |
| Target Population | Patients with macular disorders, particularly those unresponsive to standard treatments. |
| Care Setting | Outpatient settings under local anesthesia. |
Key Highlights
- First FDA-approved therapy for suprachoroidal use: Xipere (triamcinolone acetonide).
- Suprachoroidal injections provide targeted delivery with reduced systemic side effects.
- Innovative delivery systems include catheter-based and microneedle-based technologies.
- Durability of drugs in SCS influenced by particle size and relative insolubility.
- Emerging technologies like the Everads Injector show promise in clinical trials.
Guideline-Based Recommendations
Diagnosis
- Assess for uveitic macular edema and other macular disorders.
Management
- Consider suprachoroidal injections for patients unresponsive to traditional therapies.
Monitoring & Follow-up
- Monitor for therapeutic efficacy and adverse effects post-injection.
Risks
- Potential for unintended effects on anterior-segment structures.
Patient & Prescribing Data
Patients with diabetic macular edema and other macular disorders.
Suprachoroidal delivery allows for sustained drug release and targeted action.
Clinical Best Practices
- Utilize catheter-based systems for precise delivery to the SCS.
- Employ real-time imaging for confirmation of injection accuracy.
- Consider patient convenience and comfort during outpatient procedures.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.